2 weeks Ago By ABMN Staff
MannKind ( NASDAQ:MNKD – Get Free Report ) had its price target increased by analysts at Oppenheimer from $10.00 to $12.00 in a research note issued to investors on Wednesday, Benzinga reports.
The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective suggests a potential upside of 89.57% from the company’s current price.
A number of other research analysts have also recently weighed in on MNKD. Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.50 target price on shares of MannKind in a research note on Thursday, May 9th.
Rodman & Renshaw assumed coverage on MannKind in a research report on Thursday, June 13th. They issued a “buy” rating and a $8.00 target price for the company.
One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.80.
Check Out Our Latest Stock Analysis on MNKD MannKind Stock Performance MannKind ( NASDAQ:MNKD – Get Free Report ) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.
01 by $0.04. The firm had revenue of $72.
39 million for the quarter, compared to analysts’ expectations of $64.81 million. MannKind had a net margin of 3.
78% and a negative return on equity of 3.35%. The company’s quarterly revenue was up 48.
9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.02) EPS.
As a group, sell-side analysts forecast that MannKind will post 0.1 earnings per share for the current fiscal year. Insider Activity In related news, EVP Steven B.
Binder sold 5,055 shares of MannKind stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $5.94, for a total transaction of $30,026.
70. Following the completion of the sale, the executive vice president now owns 1,075,026 shares of the company’s stock, valued at $6,385,654.44.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link . In other MannKind news, EVP Steven B. Binder sold 5,055 shares of the firm’s stock in a transaction dated Thursday, August 29th.
The stock was sold at an average price of $5.94, for a total value of $30,026.70.
Following the sale, the executive vice president now owns 1,075,026 shares of the company’s stock, valued at approximately $6,385,654.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink .
Also, CEO Michael Castagna sold 85,106 shares of MannKind stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.30, for a total transaction of $536,167.
80. Following the sale, the chief executive officer now owns 2,294,836 shares of the company’s stock, valued at $14,457,466.80.
The disclosure for this sale can be found here . Over the last three months, insiders sold 92,997 shares of company stock worth $583,012. 3.
00% of the stock is owned by corporate insiders. Institutional Inflows and Outflows Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in MannKind by 8.
1% in the second quarter. AQR Capital Management LLC now owns 42,730 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 3,214 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of MannKind by 3.
4% in the second quarter. The Manufacturers Life Insurance Company now owns 101,435 shares of the biopharmaceutical company’s stock worth $529,000 after purchasing an additional 3,374 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in shares of MannKind by 6.
0% in the second quarter. Commonwealth Equity Services LLC now owns 68,361 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 3,861 shares during the period. Mission Wealth Management LP raised its stake in shares of MannKind by 18.
2% during the first quarter. Mission Wealth Management LP now owns 26,650 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 4,100 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of MannKind by 9.
0% in the first quarter. ProShare Advisors LLC now owns 65,811 shares of the biopharmaceutical company’s stock worth $298,000 after purchasing an additional 5,416 shares during the last quarter. Institutional investors own 49.
55% of the company’s stock. MannKind Company Profile ( Get Free Report ) MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Read More Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter ..
